CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes
Status:
Terminated
Trial end date:
2018-07-19
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized clinical trial for patients with recurrent type 2 diabetes
post-gastric bypass surgery that will compare a 6 month course of canagliflozin monotherapy
vs. placebo on clinical outcomes of type 2 diabetes.